Ustekinumab: 11 agencies, 2008–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PHARMAC (New Zealand) has been easier on ustekinumab than on its own caseload: it refused 0 of 5 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 17.9 years separate the first record, 26 Aug 2008 at AWMSG (Wales), from the most recent, 2026 at PBAC (Australia).
NYE METODER (Norway) changed its position: not recommended on 27 Jan 2019, recommended by 17 Jan 2021, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for ustekinumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 26 of 71 records date from 2023 or later.
The programme is broad: 27 distinct indication wordings are recorded for ustekinumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
15 of these 71 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ustekinumab, on 26 Aug 2008; CIPM (Spain) did not open a file until 20 Mar 2024 — an unusually long tail of 15.6 years between the earliest and latest system to look at it.
The record arrives in waves: 16 separate years each carry two or more decisions, spread across 18 years in total.
Restriction is doing real work here: 16 of 59 decisive outcomes narrowed ustekinumab to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales), DMC (Denmark) and NICE (England) among others.
9 of the 11 agencies here assessed ustekinumab more than once, PBAC (Australia) most often at 15 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for ustekinumab.
The full ledger for ustekinumab reads 37 recommended, 16 restricted, 6 not recommended and 5 other, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Severe chronic plaque psoriasisSevere psoriatic arthritis | Recommended | source |
| TLV (Sweden) | 23 Dec 2025 | Usymro ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| CIPM (Spain) | 20 Mar 2024 | Indicaciones terapéuticas autorizadas : Psoriasis en placas Uzpruvo está indicado para el tratamiento de la psoriasis en… | financed by the SNS · art. 92 d, e | source |
| PHARMAC (New Zealand) | 20 Dec 2022 | Crohn's disease, severe, 3rd line after infliximab and adalimumab | funding application decided · decision reached | source |
| CONITEC (Brazil) | 25 Jan 2018 | Tratamento de pacientes adultos com artrite psoriásica ativa que apresentaram resposta inadequada aos medicamentos modif… | not incorporated | source |
66 further decisions for ustekinumab, across 10 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 39 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
- lenalidomide — same ATC class L04A — Immunosuppressants
Coverage: 71 decisions for ustekinumab from 11 agencies, 2008 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.